Tag: pharmaceuticals
-
Epigenetics Biotech Secures $12.9 Million Early Financing
30 May 2014. Rodin Therapeutics Inc., a biotechnology company in Boston developing therapies based on epigenetics — inherited changes in genetic activity outside of DNA — raised $12.9 million in its first venture funding round. The company is a joint venture of Proteros biostructures GmbH in Munich and Atlas Ventures in Cambridge, Massachusetts. Rodin Therapeutics…
-
More Efficient Growth Factor Delivery Technique Devised
29 May 2014. Biologists and engineers at Georgia Institute of Technology in Atlanta developed a new process that delivers tissue-building proteins used in regenerative medicine known as growth factors in much higher concentrations than current methods. The team led by Georgia Tech bioengineering professor Todd McDevitt published its findings online yesterday in the journal Biomaterials…
-
Five Pharma Companies to Share Clinical Researcher Data
27 May 2014. Five pharmaceutical companies are joining together to share their files on researchers conducting clinical trials, to speed the administrative process of starting up new studies. The Investigator Databank is a joint project of Novartis, Janssen (a division of Johnson & Johnson), Merck, Eli Lilly and Co., and Pfizer, and administered by DrugDev,…
-
Drug Sensitivity Target Identified for Mesothelioma Therapy
27 May 2014. Researchers at the biopharmaceutical company Verastem Inc. in Cambridge, Massachusetts found the loss of a certain tumor suppressor improves responsiveness to therapies targeting cancer stem cells that treat mesothelioma, an aggressive form of lung cancer. The team led by Verastem’s research director Jonathan Pachter, with colleagues from Fox Chase Cancer Center in…
-
Pfizer, Biotech to Partner on Brown Fat Cell Research
22 May 2014. BioRestorative Therapies Inc. in Jupiter, Florida and the pharmaceutical company Pfizer Inc. in New York are conducting a joint study of human brown fat tissue and cell lines, to discover more about their use as a platform for therapies for type 2 diabetes and obesity. Financial and intellectual property aspects of the…
-
Engineered Antibody Given FDA Breakthrough Tag for Myeloma
19 May 2014. Bristol-Myers Squibb in New York says its engineered antibody elotuzumab received a breakthrough therapy designation from the U.S. Food and Drug Administration to treat multiple myeloma, when used with two other cancer drugs. Elotuzumab is being developed by Bristol-Myers Squibb and AbbVie, in North Chicago, Illinois. Multiple myeloma is a progressive cancer…
-
Antibody Developer Secures $40M from Foundation Investors
16 May 2014. Kymab Ltd., a developer of human antibodies from mouse genomes, raised $40 million in its second round of venture investment from the Wellcome Trust, an original backer of the company, and Bill & Melinda Gates Foundation. Kymab, based in Cambridge, U.K., is also collaborating with the Gates Foundation in research on discovery…
-
Laser Activation Tested as Potential Cancer Drug Delivery
16 May 2014. Researchers from University at Buffalo in New York developed and tested in the lab a process harnessing lasers to activate drugs inside the body to kill cancer cells. Findings from the proof-of-concept study, led by Buffalo’s Paras Prasad with colleagues from universities in China and Korea, were published online earlier this week…
-
Partnership to Test Genome-Driven Breast Cancer Therapies
15 May 2014. Researchers at Indiana University’s medical school in Indianapolis and Paradigm, a genomic sequencing company in Ann Arbor, Michigan are enrolling patients in a clinical study testing the ability of genomic sequencing to find optimal treatments for an aggressive type of breast cancer. The study covers women with triple-negative breast cancer, a form…
-
Biopharm Starts Genetic Heart Disease Clinical Database
14 May 2014. MyoKardia Inc., a biopharmaceutical company in South San Francisco, California, began a repository of clinical data on patients with genetic heart disorders. The database, known as Sarcomeric Human Cardiomyopathy Registry, or SHaRe, is a joint project with seven medical centers specializing in these conditions in the U.S., U.K., Netherlands, and Italy. SHaRe aims…